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1. INTRODUCTION {#dom13199-sec-0001}
===============

Patients with type 2 diabetes (T2D) who are unable to reach target glycated haemoglobin A1c (HbA1c) levels with metformin, with or without additional oral antidiabetic drugs (OADs), may be initiated on basal‐insulin (BI) therapy based on recommendations of the American Diabetes Association and the American Association of Clinical Endocrinologists 2017.[1](#dom13199-bib-0001){ref-type="ref"}, [2](#dom13199-bib-0002){ref-type="ref"}

Two new second‐generation BIs, insulin glargine 300 units/mL (Gla‐300) and insulin degludec (IDeg), with smooth action profiles and reduced risk of hypoglycaemia, have been approved recently.[3](#dom13199-bib-0003){ref-type="ref"}, [4](#dom13199-bib-0004){ref-type="ref"}, [5](#dom13199-bib-0005){ref-type="ref"} In the USA, Gla‐300 became available in 2015. The EDITION randomized controlled trial (RCT) programme demonstrated that the use of Gla‐300 leads to glycaemic control comparable to that of insulin glargine 100 units/mL (Gla‐100), with less hypoglycaemia in a wide range of T2D patients.[6](#dom13199-bib-0006){ref-type="ref"} However, in RCTs, outcomes do not always mirror those seen in the real world, and healthcare‐resource utilization (HCRU) cannot be evaluated reliably.

The interest in comparative effectiveness research, and a growing demand for real‐world data to support decision‐making, have increased the use of data sources other than RCTs (eg, electronic medical records \[EMRs\]).[7](#dom13199-bib-0007){ref-type="ref"} In view of its relatively recent introduction for clinical use in the USA, the outcomes associated with Gla‐300 therapy compared with other BIs under the conditions of routine real‐world clinical practice have not been characterized. Therefore, this study aimed to evaluate clinical outcomes, HCRU and costs in patients with T2D using BI who switched to either Gla‐300 or other BIs in real‐world clinical settings.

2. METHODS {#dom13199-sec-0002}
==========

The Differentiate Gla‐300 clinical and Economic in reaL‐world Via EMR Data study (DELIVER 2) is a retrospective cohort study. Data were collected from the Predictive Health Intelligence Environment (PHIE) database of EMRs, representing 39 integrated healthcare‐delivery networks in the USA, between March 1, 2014 and November 30, 2016 (observation period).

Eligible patients were adults (≥ 18 years of age) with T2D (identified by ICD‐9/ICD‐10 codes)[8](#dom13199-bib-0008){ref-type="ref"} who were using BI (Gla‐300, Gla‐100, insulin detemir or IDeg) during the observation period. The index date was the date of first switch to either Gla‐300 or other BIs (Gla‐100, insulin detemir or IDeg) between March 1, 2015 and May 31, 2016 (identification period). Patients were required to have ≥1 prescription for non‐index BI within 12 months prior to the index date (baseline), and were followed for 6 months after the index date (follow‐up). All patients had ≥1 HbA1c values in the 6 months before the index date and between 3 and 6 months follow‐up. Patients using \>1 BI on the index date were excluded as it is not possible to use EMR data to identify which BI those patients switched to.

The study endpoints included: change in HbA1c from baseline to follow‐up and proportion of patients reaching the pre‐specified HbA1c target \<7.0% (53 mmol/mol) and \<8.0% (64 mmol/mol) during the 6‐month follow‐up period (the latest available HbA1c measures were selected during baseline and follow‐up); incidence and event rates of hypoglycaemia identified by ICD‐9/ICD‐10 codes[8](#dom13199-bib-0008){ref-type="ref"} and/or plasma glucose level ≤ 70 mg/dL, and hypoglycaemia associated with hospitalization or emergency‐department (ED) visit during the 6‐month follow‐up period; proportion of patients requiring hospitalization, ED and outpatient services (for hypoglycaemia‐related, diabetes‐related and all‐cause events) and HCRU event rates (events/per patient per year \[PPPY\]). Cost of healthcare and cost difference were derived by multiplying the cost per event (unit cost, data source) (Appendix S1 in [File S1](#dom13199-supitem-0001){ref-type="supplementary-material"}) with adjusted mean healthcare events/PPPY and adjusted mean difference in events/PPPY between the 2 cohorts, respectively. All unit‐cost values were adjusted to 2016 US dollars using the medical‐care component of the Consumer Price Index.[9](#dom13199-bib-0009){ref-type="ref"}

To minimize confounding by indication, patients were matched 1:1 on a propensity score according to baseline demographics (age, sex, race, insurance type, geographic region), clinical features (HbA1c, BMI, Charlson Comorbidity Index score, comorbidities, hypoglycaemia), treatment (baseline BI type and concomitant drug use) and HCRU characteristics (incidence of visits) (Appendix S1 in [File S1](#dom13199-supitem-0001){ref-type="supplementary-material"}).[10](#dom13199-bib-0010){ref-type="ref"} Adjusted odds ratios (aOR), accounting for baseline hypoglycaemia/HCRU incidence, were calculated for incidence of hypoglycaemia and HCRU to compare risks between the 2 matched cohorts. Adjusted mean and least squares mean (LSM) differences were calculated for event rates of hypoglycaemia and HCRU in the 2 cohorts controlled for baseline hypoglycaemia/HCRU events.

3. RESULTS {#dom13199-sec-0003}
==========

The final unmatched cohort included 2196 patients who switched to Gla‐300, and 3837 who switched to other BIs (Appendix S2 in [File S1](#dom13199-supitem-0001){ref-type="supplementary-material"}). After propensity score matching, each cohort comprised 1819 patients with substantial aligned baseline values (Appendix S3 in [File S1](#dom13199-supitem-0001){ref-type="supplementary-material"}). Both matched cohorts were comparable in terms of sex (approximately 49% male in matched cohorts), and mean age was approximately 59.5 years. At baseline, Gla‐100 was the BI in 73.0% and 71.4% of patients in the Gla‐300 and other‐BI cohorts, respectively. The remainder of patients in each cohort switched from insulin detemir. In the other‐BI cohort, 22.4%, 66.9% and 10.7% of patients switched to Gla‐100, insulin detemir and IDeg, respectively.

At baseline, mean HbA1c was 8.95% in the Gla‐300 cohort and 8.93% in the other‐BI cohort, and significantly decreased to 8.43% and 8.43%, respectively, during follow‐up (*P* \< .001 for both cohorts). The magnitude of HbA1c changes was comparable between cohorts (−0.51% for Gla‐300 vs −0.51% for other BI; *P* = .928) (Figure [1](#dom13199-fig-0001){ref-type="fig"}A). Patients using Gla‐300 and those using other BIs were also equally likely to reach HbA1c \<7.0% (16.8% vs 18.4%, respectively; *P* = .223) and HbA1c \<8.0% (44.0% vs 44.2%, respectively; *P* = .920) during follow‐up (Appendix S4 in [File S1](#dom13199-supitem-0001){ref-type="supplementary-material"}).

![HbA1c change and hypoglycaemia during the 6‐month follow‐up period. A, Change in HbA1c^a^. B, Hypoglycaemia incidence^b^ and event rate (events/PPPY)^c^. C, Hypoglycaemia incidence^b^ and event rate (events/PPPY)^c^ associated with hospitalization/ED encounter. ^a^Comparison of mean reduction in Gla‐300 vs other basal insulin (*P* = .928). ^b^aOR: Adjusted for baseline hypoglycaemia incidence. ^c^Adjusted for baseline hypoglycaemia event rate. OTH‐BI, other basal insulin](DOM-20-1293-g002){#dom13199-fig-0001}

During follow‐up, significantly fewer patients using Gla‐300 experienced hypoglycaemia compared to those using other BIs (incidence: 15.4% vs 18.1%, respectively; *P* = .015). Patients who switched to Gla‐300 were 21% less likely to have hypoglycaemia compared to other BIs adjusted for baseline hypoglycaemia incidence (aOR = 0.79; *P* = .015). Adjusting for baseline hypoglycaemia rate, switching to Gla‐300 was associated with a 19% lower hypoglycaemia event rate at 6 months\' follow‐up (LSM difference: −0.15 events/PPPY; *P* = .041) (Figure [1](#dom13199-fig-0001){ref-type="fig"}B). A similar trend was observed for hypoglycaemia associated with hospitalization or ED visits, with patients switching to Gla‐300 having 32% fewer hypoglycaemia events related to hospitalization/ED during follow‐up (Figure [1](#dom13199-fig-0001){ref-type="fig"}C).

Patients switching to Gla‐300 had a lower risk of hypoglycaemia‐related hospitalization (33% less likely), ED services (38% less likely) and outpatient visits (23% less likely) at follow‐up compared to those switching to other BIs (aOR: hospitalization, 0.67 \[*P* = .037\]; ED services, 0.62 \[*P* = .007\]; outpatient visits, 0.77 \[*P* = .011\]) (Figure [2](#dom13199-fig-0002){ref-type="fig"}A). The outcomes of overall diabetes‐related and all‐cause HCRU incidences were favourable for Gla‐300, showing a significant reduction in the risk of requiring ED services (Appendix S5 in [File S1](#dom13199-supitem-0001){ref-type="supplementary-material"}).

![Hypoglycaemia‐related healthcare‐resource utilization during the 6‐month follow‐up period. A, Patients requiring^a^ hypoglycaemia‐related healthcare‐resource utilization. B, Event rate^b^ of hypoglycaemia‐related healthcare‐resource utilization. ^a^aOR: adjusted for baseline healthcare‐resource utilization incidence. ^b^Adjusted mean event rate: adjusted for baseline healthcare‐resource utilization event rate](DOM-20-1293-g001){#dom13199-fig-0002}

There were significantly fewer adjusted hypoglycaemia‐related ED events (42% fewer) during follow‐up in patients treated with Gla‐300 (LSM difference: −0.09 events/PPPY; *P* = .012) (Figure [2](#dom13199-fig-0002){ref-type="fig"}B), which resulted in savings of US \$161 PPPY. Considering all hypoglycaemia‐related HCRU including hospitalizations, ED and outpatient visits, switching to Gla‐300 resulted in overall savings of US \$1439 PPPY. Patients switching to Gla‐300 also experienced significantly fewer diabetes‐related ED events (28% fewer) during follow‐up compared to patients switching to other BIs, which translated to savings of US \$138 PPPY. Fewer all‐cause ED and outpatient events during follow‐up in patients treated with Gla‐300 resulted in savings of US \$185 and US \$69 PPPY for the 2 outcomes, respectively (Appendix S6 in [File S1](#dom13199-supitem-0001){ref-type="supplementary-material"}).

4. DISCUSSION {#dom13199-sec-0004}
=============

Real‐world studies provide information that is complementary to RCTs and may be more generalizable and pertinent to clinicians and healthcare‐delivery systems.[11](#dom13199-bib-0011){ref-type="ref"} In this real‐world study with well‐balanced matched cohorts, patients switching to Gla‐300 reached similar HbA1c control with a lower risk of hypoglycaemia events compared with those switching to other BIs. In addition, patients using Gla‐300 had a lower risk of requiring hypoglycaemia‐related, diabetes‐related and all‐cause ED services. This lower HCRU translated to lower costs in patients using Gla‐300.

This is the first real‐world study examining the comparative effects of switching to Gla‐300 from another BI in patients with T2D. The results showing comparable HbA1c reduction and reduced hypoglycaemia with Gla‐300 are consistent with results from the phase III EDITION RCT programme. Real‐world evidence concerning switching to Gla‐300 is very limited. A recent medical chart study showed that switching to Gla‐300 from another BI resulted in significantly lower HbA1c, hypoglycaemia events and frequency of dosing.[12](#dom13199-bib-0012){ref-type="ref"} However, that study compared only data before and after switching, without a comparator cohort. In our study, HbA1c was significantly improved in both cohorts, although the residual mean HbA1c level was still relatively poor (\>8.0%), reflecting that treatment may not be sufficiently intensified in the real‐world clinical practice. The results of HbA1c control are similar to those of other studies, which can be explained by the fact that a suboptimal HbA1c level is one of the potential reasons for insulin switching. Nevertheless, our data provide real‐world evidence of effectiveness, that is, switching to Gla‐300 from other BIs (mainly Gla‐100) is associated with benefits in terms of reduced hypoglycaemia. Insulins with a lower risk of hypoglycaemia may lead to better adherence to and persistence with therapy, and potentially, to longer‐term glycaemic control.[13](#dom13199-bib-0013){ref-type="ref"}, [14](#dom13199-bib-0014){ref-type="ref"}

This study demonstrated that switching to Gla‐300 is associated with reduction in HCRU, which could result in significant cost savings in patients with T2D. The different prescribing patterns based on insurance coverage in our study, which remained even after propensity score matching, suggest that up‐front medication costs may be driving some prescription decisions. The better health‐economic outcomes with Gla‐300 shown here may provide important information to healthcare professionals, patients and payers when considering the overall cost consequences of prescribing decisions.

These results should be interpreted in light of certain limitations resulting from the retrospective nature of the real‐world design. Patients from the PHIE EMR database were, for the most part, from the Midwest and Southern regions of the USA, which could limit extrapolating the results to other regional populations. Patients included in the study were early users of second‐generation basal insulins; therefore, the sample size was limited and the patients\' demographics and clinical characteristics might differ from basal insulin‐experienced patients in general. The follow‐up period in this study is relatively short, although it is on a par with or longer than that of most RCTs. The study is likely to underreport overall hypoglycaemia, as only clinically significant events were captured and there were no self‐monitored blood‐glucose or continuous blood‐glucose monitoring data in the database. Thus, the treatment effect on hypoglycaemia could be underestimated. The reason for switching was not available from the EMRs, so selection bias may not be completely excluded after propensity score matching. The diabetes‐related HCRU was identified based on ICD‐9/ICD‐10 codes,[8](#dom13199-bib-0008){ref-type="ref"} but EMR data may not link the actual diagnosis name, which could result in misclassification. The unit cost of HCRU may differ based on integrated‐delivery‐network size, features, geographic location, etc. However, the current analysis and data should provide a useful perspective on potential cost savings related to the lower HCRU resulting from a reduction in hypoglycaemia events.

In conclusion, the current study provides the first comparative real‐world evidence concerning the benefits of switching to the new‐generation BI Gla‐300. From the perspective of healthcare practitioners and healthcare systems, the clinical benefits of lower hypoglycaemia associated with Gla‐300 translated to less HCRU. With the known increased economic burden of T2D care on the healthcare system, less HCRU and associated cost‐savings can be an important consideration for payers. Considering the limited sample size because of the early users in this study, further research with a larger sample size will be needed.
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